Advanced gastro-oesophageal cancer survival benefit with first-line nivolumab

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Sep 29 / Springer Healthcare

Advanced gastro-oesophageal cancer survival benefit with first-line nivolumab

Oncology Gastrointestinal Cancer Cancer Immunotherapy ESMO-2020

Description

Markus Moehler describes the CheckMate 649 trial findings showing improved survival outcomes with the combination of first-line nivolumab and chemotherapy for individuals with advanced gastric, gastro-oesophageal junction and oesophageal cancers.

Related Content

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.